Based on our preclinical data showing an increased infiltration of cytotoxic immune cells in the tumor microenvironment of ACB-1801-treated tumors, which are further supported by clinical results, our results provides a framework for rational combination immunotherapy development of ACB-1801 and anti-PD-1. Here, PDCD1 is linked to neoplasm.